The AntiHelix consortium includes five renowned academic laboratories with a long-standing interest in the field of DNA helicases (CNR, UCPH, USFD, ELETTRA, SLU), with a wide range of technical and scientific expertises, ranging from cell biology to biochemistry to structural biology, and working on different but interconnected DNA helicases; one world leader in the field of single molecules biophysical studies of protein-DNA interaction (VU); one research group dedicated to clinical oncology studies (UKESSEN); three companies involved in various stages of drug discovery (LDC, EDELRIS, PPSC) and one company developing state-of-the-art instrumentation for biophysical studies (LUMICKS). This web of research groups and institutions will provide a thriving and innovative scientific environment that potentially offers unique opportunities to develop a strong research programme at the interface between different disciplines (cell biology, biochemistry, structural biology, biophysics, single molecule approaches, optics, medicinal chemistry, drug design, computational biology/chemistry, clinical oncology) with complementary experimental approaches and a strong emphasis on translation of scientific results.
Voting members:
|
Non-voting members:
|
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 859853